You just read:

Limited improvement in EGFR testing rates observed in new survey with approximately one in five advanced lung cancer patients still at risk of missing out on targeted therapy

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

07 Dec, 2016, 09:00 ET